<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01798875</url>
  </required_header>
  <id_info>
    <org_study_id>POLovaRIS</org_study_id>
    <nct_id>NCT01798875</nct_id>
  </id_info>
  <brief_title>PCOS, Therapy and Markers of Cardiovascular Risk</brief_title>
  <official_title>Effects of Different Therapies on Surrogate Markers of Cardiovascular Risk in Women With Polycystic Ovary Syndrome (PCOS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Gdansk</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Gdansk</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In addition to chronic anovulation and hyperandrogenemia, polycystic ovary syndrome (PCOS) is
      also characterized by peripheral insulin resistance and hyperinsulinaemia, which in turn lead
      to the development of diabetes, hypertension, atherosclerosis and coronary heart disease.
      Serum markers of inflammation are being increasingly recognized as predictors of
      atherosclerosis and cardiovascular risk, and chronic low-grade inflammation has been recently
      proposed to play a role in the pathogenesis of metabolic syndrome and type 2 diabetes
      mellitus. Therefore, the aim of the present study is to evaluate the effects of commonly used
      non-pharmacologic (diet and lifestyle change) and pharmacologic (oral contraceptives,
      metformin, anti-androgens) treatment strategies on classical and surrogate cardiovascular
      risk markers in women with PCOS. The study hypothesis is that some of the commonly used
      therapies of women with PCOS may have more favorable effects on classical and surrogate
      markers of cardiovascular risk then others or some of them may even confer a higher risk of
      cardiovascular events
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum C-reactive protein (CRP) levels</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>PCOS</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral metformin at a dose of 850mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral contraceptive</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral contraceptive containing 35ug of ethynylestradiol and 2mg of cyproterone acetate (21 day regimen)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral metformin</intervention_name>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral contraceptive</intervention_name>
    <arm_group_label>Oral contraceptive</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PCOS

        Exclusion Criteria:

          -  diabetes

          -  pregnancy

          -  contraindications to oral contraceptives
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Clinical and Experimental Endocrinology, Medical University of Gdansk</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominik Rachon, MD, PhD</last_name>
      <phone>+48583491947</phone>
      <email>drachon@gumed.edu.pl</email>
    </contact>
    <investigator>
      <last_name>Monika Kuligowska-Jakubowska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jolanta Dardzinska, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Agnieszka Kowalewska-Wlas, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aleksandra Rutkowska, MSc, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Justyna Breska-Kruszewska, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2013</study_first_submitted>
  <study_first_submitted_qc>February 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2013</study_first_posted>
  <last_update_submitted>February 28, 2013</last_update_submitted>
  <last_update_submitted_qc>February 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Gdansk</investigator_affiliation>
    <investigator_full_name>Dominik Rachon</investigator_full_name>
    <investigator_title>M.D. PhD</investigator_title>
  </responsible_party>
  <keyword>pcos</keyword>
  <keyword>metformin</keyword>
  <keyword>oral contraception</keyword>
  <keyword>cyproterone acetate</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Cyproterone Acetate</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

